Compare SLDB & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLDB | LAB |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.9M | 488.4M |
| IPO Year | 2018 | 2011 |
| Metric | SLDB | LAB |
|---|---|---|
| Price | $6.62 | $1.54 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 2 |
| Target Price | ★ $14.70 | $1.35 |
| AVG Volume (30 Days) | 1.0M | ★ 1.6M |
| Earning Date | 03-05-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $169,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 79.77 |
| 52 Week Low | $2.41 | $0.92 |
| 52 Week High | $7.37 | $1.81 |
| Indicator | SLDB | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 64.57 | 53.56 |
| Support Level | $5.26 | $1.50 |
| Resistance Level | $5.96 | $1.67 |
| Average True Range (ATR) | 0.41 | 0.10 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 83.74 | 70.13 |
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.